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Abstract
Introduction: To investigate the outcome of locoregionally advanced nasopharyngeal carcinoma (NPC) treated
with intensity-modulated radiation therapy (IMRT) after induction chemotherapy, with or without concomitant
chemotherapy.
Methods: Between August 2003 and March 2007, 370 patients with locoregionally advanced NPC were treated
with IMRT. Presenting stages were stage IIB in 62, stage III in 197, and stage IVA/B in 111 patients. All patients
except for 36 patients with cervical lymphadenopathy of 4 cm or less in diameter received 2 cycles of cisplatin-
based neoadjuvant chemotherapy. Forty-eight patients received cisplatin-based concurrent chemotherapy as well.
Results: With a median follow-up time of 31 months (range 5 to 61 months), the 3-year local control, regional
control, metastasis-free survival (MFS), disease-free survival (DFS) and overall survival (OS) rates were 95%, 97%, 86%,
81% and 89%, respectively. Multivariate analyses revealed that both age (≤ 60 vs. >60) and N-classification are
significant prognosticators for OS (P = 0.001, hazard ratio [HR] 2.395, 95% confidence interval [CI] 1.432-4.003; P =
0.012, hazard ratio [HR] 2.614, 95% confidence interval [CI] 1.235-5.533); And N-classification is the only significant
predicative factor for MFS (P = 0.002, [HR] 1.99, 95% CI 1.279-3.098). T-classification and concurrent chemotherapy
were not significant prognostic factors for local/regional control, MFS, DFS, or OS. Subgroup analysis revealed that
concurrent chemotherapy provided no significant benefit to IMRT in locoregionally advanced NPC, but was
responsible for higher rates of grade 3 or 4 acute toxicities (50% vs. 29.8%, P < 0.005). No grade 3 or 4 late toxicity
including xerostomia was observed. However, two patients treated with IMRT and neoadjuvant but without
concurrent and adjuvant chemotherapy died of treatment related complications.
Conclusion: IMRT following neoadjuvant chemotherapy produced a superb outcome in terms of local control,
regional control, MFS, DFS, and OS rates in patients with stage IIB to IVB NPC. Effective treatment strategy is
urgently needed for distant control in patients diagnosed with locoregionally advanced NPC.
Background
Nasopharyngeal cancer (NPC) is the most commonly
diagnosed head and neck malignancy in Southeast Asia,
and radiation therapy is its mainstay treatment modality.
For locoregionally-advanced diseases, concurrent che-
moradiation therapy is considered the standard of
treatment. Chemotherapy delivered concurrently with
conventional radiotherapy has been shown to improve
local control, disease-free survival, as well as overall sur-
vival rates for NPC patients with T2B, T3 or T4 dis-
eases, or with neck lymphadenopathy [1-5].
Intensity-modulated radiation therapy (IMRT) enables
the delivery of higher radiation dose to the primary dis-
ease and neck metastases while sparing the organs/tis-
sues at risk (OARs) thereby enhancing the therapeutic
ratio. It has been accepted as a more advantageous
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tion for NPC. The clinical advantages of IMRT in the
treatment of NPC with respect to both disease control
and adverse-effect profiles have been repeated demon-
strated [6-10]. The local control and regional control
were particularly encouraging after IMRT, exceeding
95% in some of the previous reports [7-10].
Although considered essential for patients with locore-
gionally advanced NPC, the therapeutic value of che-
motherapy given concurrently with IMRT and the
optimal strategy of combining utilization of chemother-
apy and IMRT have not been sufficiently addressed. The
rationale of concurrent chemotherapy with IMRT in the
management of NPC was largely derived from experi-
ence with conventional radiotherapy. With local and
regional control rates both approximating 95% after
IMRT, it is reasonable to question whether chemother-
apy offers equal therapeutic benefits to all subgroups of
patients with locoregionally advanced NPC, i.e., patients
with T2B, T3, T4, and/or limited N+ classification such
as N1/2 disease. The aim of this report is to address the
treatment outcome and to elucidate the efficacy of con-
current chemotherapy in NPC treated with IMRT by
analyzing the outcome of a relatively large group of
patients with locoregionally advanced NPC treated uni-
formly with IMRT following neoadjuvant chemotherapy,
with or without concurrent chemotherapy.
Methods
Patients and pretreatment evaluation
Between August 2003 and March 2007, 382 histologi-
cally diagnosed non-metastatic nasopharyngeal carci-
noma (NPC) patients were treated primarily with
intensity-modulated radiation therapy (IMRT) according
to an IRB approved institutional treatment protocol at
Fujian Provincial Tumor Hospital. Pretreatment evalua-
tion consisted of a complete history and physical exami-
nation, flexible fiberoptice n d o s c o p i ce x a m i n a t i o n ,
complete blood counts, blood chemistries, urinalysis,
chest X-ray, electrocardiogram, computed tomography
(CT) scans of the nasopharynx and neck, bone emission
computed tomography (ECT) scans, ultrasound of liver
and abdominal lymph nodes, and dental evaluation.
Magnetic resonance imaging (MRI) scans of the head
and neck were performed instead of CT in all patients
diagnosed after July 2005. Positron emission tomography
(PET) scans, CT scans of the chest and abdomen were
optional and were performed when clinically indicated.
Tumors were staged according to the AJCC (1997)
cancer staging classification [11]. Patients who had evi-
dence of distant metastasis were not eligible for this
treatment protocol. Ten (10) patients who had early
stage (i.e., T1N0M0 or T2N0M0) diseases, as well as 2
patients who did not complete the planned radiation
u s i n gI M R Tt od e f i n i t i v ed o s ew e r ee x c l u d e df r o mt h i s
analysis. Characteristics of the remaining 370 patients
with stage IIB to IVB NPC are listed in Table 1.
Radiation Therapy Techniques
The techniques of planning and delivery of IMRT were
described previously [10]. Briefly, all patients were
immobilized in the supine position with thermoplastic
masks. CT scans with IV contrast using 3 mm slices
from the head to the level of 2 cm below the sternocla-
vicular joints were performed for planning. CT scan
only were used for target delineation prior to July 2005,
and planning CT scans with MRI-CT fusion using co-
registration software (Oncentra Materplan® version 1.5)
were performed after July 2005 for all patients.
The primary and nodal gross tumor volumes (GTV-P
and GTV-N) included all gross diseases visualized on
CT and/or MRI. The high-risk clinical tumor volume
(CTV-1) included GTV plus 5-10 mm margin and
encompassed the entire nasopharyngeal mucosa plus 5
mm submucosal volume. CTV-2 was designed for
potentially involved regions included the nasopharyngeal
cavity (limited only to the posterior part of nasal cavity),
maxillary sinus (limited to 5-mm anterior to the poster-
ior nasal aperture and maxillary mucosa), pterygopala-
tine fossa, posterior ethmoid sinus, parapharyngeal
Table 1 Patient characteristics
Number of patients
With concurrent
chemotherapy
Without concurrent
chemotherapy
P Value
Age, year P = 0.1
≥ 60 44 263
<60 4 59
Gender P = 0.02*
Male 43 238
Female 5 84
Histology N/A
WHO
Type I
02
WHO
Type II
20
WHO
Type III
46 319
Stage P = 0.02*
IIB 2 60
III 36 161
IVA/B 10 101
KPS P = 0.77
90 42 283
80-90 6 36
70-80 0 3
* Significantly lower proportions of male and patients with stage IVA/B
received concurrent chemotherapy as compared to female and patients with
stage III disease.
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vertebra, inferior spheniod sinus and cavernous sinus,
and included the retropharyngeal lymph nodal regions
from the base of skull to cranial edge of the second cer-
vical vertebra. The CTV of the neck nodal regions
(CTV-N) included level II, III, IV, V, which were out-
lined according to the recommendation by the RTOG/
EORTC CTV delineation protocol for head and neck
malignancies (Figures 1) [12]. The planning target
volume (PTV) was created based on each volume with
an additional 3-mm margin, allowing for setup variabil-
ity. Critical normal structures including the brainstem,
spinal cord, parotid glands, optic nerves, chiasm, lens,
eyeballs, temporal lobes, temporomandibular joints,
mandible, hypophysis were contoured and set as OARs
during optimization.
The primary tumor and upper neck above the bottom
of hyoid bone (level II and upper level V) was treated
with IMRT techniques using seven coplanar beams,
separated at 51° apart. Inverse treatment planning using
the Plato treatment planning software systems (RTS®
version 2.6.4) was used for all patients. A mono-iso-
centric technique was used for all these fields with the
isocenter set at the center of GTV-P. The radiation dose
prescribed in the protocol evolved: Before July 2006, a
t o t a ld o s eo f6 6G y3 0f r a c t i o na t2 . 2G y / f r a c t i o nt ot h e
GTV-P and GTV-N, 60 Gy at 2 Gy/fraction to the
CTV-1, 54 Gy at 1.8 Gy/fraction to CTV-2 and CTV-N
were prescribed; After July 2006, a total dose of 69.75
Gy in 31 fraction at 2.25 Gy/fraction to the GTV-P,
66.65 Gy at 2.15 Gy/fraction to the GTV-N, 60.45 Gy at
1.95 Gy/fraction to the CTV-1, 55.8 Gy at 1.8 Gy/frac-
tion to CTV-2 and CTV-N were prescribed. This change
of prescription was approved by our institution for the
protocol. All patients were treated with one fraction
daily, 5 days per week. The dose received by each OAR
should less than its tolerance limit according to the
RTOG 0225 protocol. The volume of each parotid
received >26 Gy dose should no more than 50%. A con-
ventional technique (AP field) was used for the lower
neck (level III, level IV, lower level V). It was treated
with 28 fractions of 1.8 Gy/fraction, to a total dose of
50.4 Gy with a depth of 3 cm from the anterior surface.
The IMRT field was matched with the AP field with a
split-beam technique, as described previously [13].
Treatment was delivered with a computer-controlled
auto sequence multi-leaf collimator (MLC) on a linear
accelerator (Eleckta Precise®) equipped with 40-leaf
MLC.
Seventy-three (73) patients received boost treatment
after the planned course of IMRT because of gross resi-
dual disease (i.e., less than 100% resolution of the pri-
mary disease) observed on follow-up CT or MRI or
during nasopharyngoscopy. Among these patients, 20
were treated with brachytherapy boost with a dose of 6-
12 Gy (2-3 Gy/fraction, 2 fracion/day), and external
beam radiation were used in the remaining 53 patients
to a total dose of 6-12 Gy at 2.2-3 Gy per daily fraction.
Twenty-eight (28) patients received boost irradiation
(4.5-10 Gy) to the cervical lymph nodes for residual ade-
nopathy of more than 1 cm in diameter on follow-up
CT or MRI.
Chemotherapy
To prevent disease progression during treatment plan-
ning and waiting prior to the start of definitive treat-
ment using IMRT, neoadjuvant chemotherapy was given
to 308 patients with AJCC stage III-IVB diseases and 26
stage IIB patients with neck adenopathy of more than 4
cm in diameter. Thirty-six patients whose neck
Figure 1 Selected CT slides for demonstrating the delineation
of target volumes. (Red line: GTV-P and GTV-N; Orange line: CTV-1;
Blue line: CTV-2; Yellow line: CTV-N).
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receive neoadjuvant chemotherapy. Neoadjuvant che-
motherapy consisted of 2 cycles of cisplatin (80 mg/m
2
IV in days 1-3) plus 5-FU (800 mg/m
2 IV in d1-d5) or
paclitaxel (135 mg/m
2 IV on the first day) spaced 2
weeks apart prior to the initiation of IMRT treatment,
and IMRT started within 1 week after the second cycle
of chemotherapy. Concurrent and adjuvant chemother-
apy was not part of this standardized protocol for NPC
treatment; nevertheless, concurrent cisplatin-based che-
motherapy (cisplatin 80-100 mg/m
2 given over day 1-3
of each 21-day cycle) was given to 48 patients at the dis-
cretion of the attending radiation oncologists. In addi-
tion, adjuvant cisplatin-based chemotherapy was given
to 71 patients at the discretion of the attending radia-
tion oncologists.
Follow-up
All patients were evaluated weekly during radiation ther-
apy, and were required to be followed-up by their
attending radiation oncologist after the completion of
their treatment every 3 months in the first 2 years, every
6 months from year 2 through year 5, and annually
thereafter. Each follow-up included a complete examina-
tion, basic serum chemistry, chest X-ray, and ultrasound
of liver and abdomen. Flexible fiberoptic endoscopy was
performed at every visit after treatment. MRI of the
head and neck areas was performed every 6 months.
Treatment induced toxicities were accessed and scored
according to the RTOG radiation morbidity scoring cri-
teria at each follow-up [14].
Statistics
The actuarial local/regional control, metastatic-free sur-
vival, disease-free survival, and overall survival rates
were calculated by the Kaplan-Meier method. The dura-
tion of time to locoregional failure and distant metasta-
sis was measured from the date of the completion of
radiation therapy (including boost irradiation) until
documented treatment failure. The duration of overall
survival was calculated from diagnosis until death or
until death or until the date of the last follow-up visit
for patients still alive.
Log-rank test was used to detect the significant differ-
ence in survivals between different prognostic groups.
Multivariate analysis using the Cox proportional hazard
model was performed for the aforementioned endpoints
to define independent predictors among various poten-
tial prognostic factors.
Results
Treatment outcomes
The median follow-up time for the entire group was 31
months (range 5 to 61 months). At the time of their last
follow-up, 15, 10, and 46 patients had developed local,
regional, and distant metastasis, respectively, including 5
cases with both distant and local/regional recurrences.
The 3-year estimated local control, regional control,
metastasis-free survival (MFS), disease-free survival
(DFS) and overall survival (OS) were 95%, 97%, 86%,
81% and 89%, respectively.
Thirty-eight (10.3%) patients had deceased at the time
of this analysis: 22 patients died from distant metastasis,
7 died from progression of locoregional disease after
recurrence. One patient died from late complication
caused by radiation therapy (septicemia secondary to
untreated infection occurred in the post-nasal space) at
12 months, and 1 patient died of bleeding from naso-
pharynx at 6 months after the completion of treatment.
Both deaths were considered as treatment related. In
addition, 3 patients died from co-morbidities unrelated
with NPC, 1 died from traffic accident, and the causes
of death of 3 additional cases were not reported.
Among all patients with local or regional failures, 1, 4,
8, and 8 had T1, T2, T3, or T4 diseases, and 0, 11, 10, 0
had N0, N1, N2, N3 diseases, respectively. Therefore,
50%, 3.3%, 5.8%, and 19.1% of patients with T1 to T4
diseases, and 0%, 8.1%, 5.3%, and 0% of patients with
N0 to N3 diseases experienced local or regional recur-
rence, respectively. The regional control of patients with
N0, N1, N2, and N3 diseases were 100%, 96.7%, 96.9%,
and 100%, respectively (P = 0.62). No significant correla-
tion can be found between T- and N-classifications with
local and/or regional recurrences.
Among all patients with distant metastasis, 0, 12, 19,
and 15 had T1, T2, T3, or T4 diseases, and 1, 10, 29, 6
had N0, N1, N2, N3 diseases, respectively. The associa-
tions between cervical nodal status and MFS, DFS, and
OS rates were presented in Table 2. Figures 2 and Figure
3 illustrate the association between OS and MFS with
neck node status (N-classification).
No significant association could be detected between
the outcome including MFS, DFS, or OS and T-classifi-
cation. No significant improvement in local and/or
regional control rates as well as 3-year MFS, DFS or OS
could be detected between patients received IMRT with
or without concurrent chemotherapy (Tables 3 and 4).
Analyses for MFS, DFS, or OS for patients with cervical
lymphadenopathy or extensive lymph adenopathy also
Table 2 Three-year overall survival rates according to
patients’ N-classification
N0 N1 N2 N3 P Value
DFS 93.3 84.9 76.3 73.9 0.07
MFS 93.3 92.2 81.2 73.7 0.007
OS 100 91.2 88 73.9 0.006
Abbreviations: MFS: metastatic-free survival rate; DFS: disease-free survival
rate; OS: overall survival rate
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ted using IMRT with or without concurrent chemother-
apy (Tables 5 and 6).
Acute and late toxicity
All 370 patients tolerated the treatment well and com-
pleted the planned therapy. The most commonly
observed severe (i.e., grade 3 or 4) acute toxicities
included grade 3 mucositis, skin desquamation, and leu-
cocytopenia, which occurred in 89(27.5%), 15(4.6%), and
19(5.9%) patients, respectively. One patient presented
grade 4 leucocytopenia. The total incidence of grade 3
or 4 acute toxicities in patients received IMRT plus con-
current chemotherapy was 50%, significantly higher than
those received IMRT alone (29.8%) (P < 0.005).
The most commonly observed late effect was xerosto-
mia. The severity of xerostomia was evaluated at 3, 6,
12, and 24 months after radiotherapy. A total of 5.1%
and 94.9% patients complained of grade 1 or 2 xerosto-
mia, respectively, at 3 months. The severity of xerosto-
mia diminished over time, and the detectable
xerostomia at 24 months was 7.8%. No grade 3 or 4 xer-
ostomia or other late-effects was detected. Two patients
developed infection or bleeding followed by necrosis in
the post-nasal space after treatment at 12 and 6 months
respectively. Both patients received radiation therapy
Figure 2 Kaplan-Meier estimate of overall survival according to
N-classifications.
Figure 3 Kaplan-Meier estimate of metastatic-free survival
according to N-classifications.
Table 3 Local and/or regional control of disease treated
with or without concurrent chemotherapy
No concurrent
chemotherapy
With concurrent
chemotherapy
P Value
Local control 94.7% 97.8% 0.62
Regional
control
97.4% 96.8% 0.96
Locoregional
control
93% 94.6% 0.8
Table 4 Three-year survival rates in patients treated with
or without concurrent chemotherapy
No concurrent
chemotherapy
With concurrent
chemotherapy
P
Value
MFS 85.8% 84.5% 0.65
DFS 80.3% 82.6% 0.48
OS 89.2% 89.1% 0.82
Table 5 Three-year survival in the 346 patients with
N+ disease treated with vs. without concurrent
chemotherapy
No concurrent
chemotherapy
With concurrent
chemotherapy
P Value
MFS 82.5 83.7 0.50
DFS 79.3 81.7 0.66
OS 88.3 88.5 0.85
Table 6 Three-year survival in the 210 patients with
N2-3 disease treated with or without concurrent
chemotherapy
No concurrent
chemotherapy
With concurrent
chemotherapy
P Value
DFS 74.6 81.7 0.24
MFS 79.3 84 0.22
OS 85.8 89.3 0.71
Lin et al. BMC Cancer 2010, 10:39
http://www.biomedcentral.com/1471-2407/10/39
Page 5 of 9after neoadjuvant chemotherapy without concurrent and
adjuvant chemotherapy. And both patients declined
medical attention and deceased, and were considered as
grade V toxicity.
Prognostic factors
The value of various potential prognostic factors include
age, gender, stage, use of boost and use of chemotherapy
on predicting local control, MFS, DFS, and OS rates
were evaluated in multivariate analysis. The number of
local or regional failures was too small to allow mean-
ingful analysis, and no prognostic factor was significant
for local or regional control.
T-classification was not a significant prognostic factor
for local/regional control, MFS, DFS, or OS. N-classifi-
cation and age (≤ 60 vs. >60) were found to be the inde-
pendent predictors for overall survival (P = 0.001,
hazard ratio [HR] 2.395, 95% confidence interval [CI]
1.432-4.003; P = 0.012, hazard ratio [HR] 2.614, 95%
confidence interval [CI] 1.235-5.533); furthermore, N-
classification was a significant prognostic factor for
metastasis-free survival (P = 0.002, [HR] 1.99, 95% CI
1.279-3.098).
Concurrent and adjuvant chemotherapy provided no
significant additive effect on local/regional control, MFS,
DFS, and OS rates in this group of patients with locore-
gionally advanced NPC, regardless of their T-classifica-
tion or nodal status, definitively treated with IMRT in
multivariate analysis (P > 0.05).
Discussion
Concurrent chemoradiation therapy has been considered
as the standard modality of locoregionally advanced
NPC [15]. Although the efficacy of chemotherapy used
in concomitant with conventional radiation therapy has
been repeatedly proven [1-5], the additive value of con-
current chemotherapy on local/regional control and sur-
vival rates for locoregionally advanced NPC treated with
IMRT is largely unknown. The results of the current
study demonstrated that the local control rate of
patients with T2b-T4 NPC was 95%, and the regional
control of patients with cervical lymphadenopathy,
regardless of its extent, was 97% at three-years after
IMRT following cisplatin-based neoadjuvant chemother-
apy. The metastasis-free survival (MFS), disease-free sur-
vival (DFS), and overall survival (OS) rates were 86%,
81%, and 89%, respectively, indicating that distant
metastasis remained the major cause of treatment fail-
ure. Furthermore, multivariate analyses revealed that no
significant prognostic factor including T-classification
and concurrent chemotherapy were identified for local
and/or regional control after neoadjuvant chemotherapy
plus IMRT for this group of patients with locoregionally
advanced NPC. Although patients’ age was significant
for predicting the overall survival rate, the N-classifica-
tion was the only significant prognostic factor for both
MFS and OS. Our data suggested that the use of con-
current chemotherapy added little value to local and dis-
tant disease control for patients with locoregionally
advanced NPC treated with neoadjuvant chemotherapy
and IMRT.
Despite of the proven efficacy of chemotherapy deliv-
ered concurrently with conventional radiation, the com-
bined treatment strategy comes with substantial
adverse-effects. In the pivotal Intergroup 0099 trial,
grade 3 and 4 adverse effects in patients treated with
concurrent chemoradiation therapy nearly doubled
those received irradiation only. In addition, 37% patients
discontinued concurrent chemoradiation therapy prema-
turely due to intolerance to combined treatment [1].
Similar results on treatment-induced complications have
been documented in randomized and retrospective stu-
dies [2-4,16]. Obviously, treatment induced side effects
could impede the utilization of concurrent chemoradia-
tion, thus adversely affect the treatment outcome for
patients with locoregionally advanced NPC. Relatively
favorable outcome in terms of both local/regional con-
trol and overall survival were observed in the current
study. These results indicated that concurrent che-
motherapy that significantly increases the probability
and severity of treatment-induced side effects might not
be essential in the treatment of NPC if IMRT is used.
We consider our results important as it suggests that
omission of concurrent chemotherapy maybe possible,
and effective disease control in the primary area and
cervical nodes can be achieved with improvement in
radiation technology and utilization of sequential
chemotherapy.
Chemotherapy provides two purposes in the treatment
of NPC: to improve local and regional control by
improving the radio-sensitivity, and to further improve
overall survival by controlling subclinical distant meta-
static foci. In the aforementioned Intergroup study
reported by Al-Sarraf, patients with stage III or IV NPC
staged according to the 1992 AJCC staging system
(including T2BN1M0 disease staged according to the
revised 1997 system) were treated with either radiother-
apy alone or concurrent chemoradiation therapy after
randomization. The results of this pivotal study revealed
that concurrent chemoradiation therapy significantly
improve the local control, disease-free and overall survi-
val rates [1]. These favorable results were subsequently
confirmed by a number of randomized clinical trials
completed in Asia and a meta-analysis [2-5]. However,
for patients with stage IVB diseases, the rate of distant
metastasis approached 40% despite aggressive che-
motherapy [4]. Furthermore, previously reported results
from randomized trials on neoadjuvant or adjuvant
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dosage, and intensity failed to demonstrate any survival
benefit from chemotherapy [5,17]. Thus, it is reasonable
to speculate that improved local and/or regional control
was the underlying mechanism of the improved survival
for patients treated with concurrent chemoradiotherapy.
The 3-year overall survival rate of 89% without concur-
rent chemotherapy in the current series further sug-
gested that improved local and regional control rates
could result in an improved overall survival.
With the increasing utilization of IMRT in the treatment
of NPC, improved outcome in terms of local and regional
controls had been repeatedly demonstrated. The three-
year local/regional control and overall survival rates were
reportedly in the range of 90%-95% and 80%-85%, respec-
tively [7-10]. Improved local and regional controls were
anticipated with improved dose coverage of gross and clin-
ical tumor volumes. However, conventional technique was
used in the aforementioned randomized trials on current
chemoradiotherapy, and all patients with locoregionally
advanced NPC reported in the IMRT trials received con-
current chemotherapy. Therefore, the effect of chemother-
apy on locoregional control remained uncertain in NPC
patients definitively treated with IMRT. Our results
demonstrated that for patients with stage IIB to IVB dis-
eases, neoadjuvant chemotherapy followed by IMRT pro-
duced a superb outcome, and no difference was detected
when compared to those treated with concurrent chemor-
adiation. Our DFS and OS rates reported exceed those of
patients treated with concurrent chemoradiation reported
in randomized clinical studies including the Intergroup
0099 trial. Although direct comparison of results from dif-
ferent clinical trials is not feasible, substantial improve-
ment from the superb local and regional control rates of
>95% may require a paradigm shift in the current che-
motherapy strategy.
A sf a ra sw ek n o w ,t h i si st h ef i r s ts t u d yt oa d d r e s s
the outcome for locoregionally advanced NPC treated
using IMRT with or without concurrent chemotherapy.
Although no difference was shown between patients
treated with or without concurrent chemotherapy, we
consider our results far from conclusive. Firstly, among
the 370 patients included in the current analysis, less
than 50 received concurrent chemotherapy. The imbal-
ance in these two subgroups of patients made the inter-
pretation of our results difficult. However, since the 3-
year local and regional control rates equaled 95% and
97%, respectively for patients treated without concurrent
chemotherapy, detecting significant improvement with a
magnitude of 1%-2% from such superb outcome is unli-
kely even with a substantial number of patients in both
arms. In addition, a significant improvement in the 3-
year overall survival from 90% is also unlikely with an
improved balance between the two arms. Secondly, the
median follow-up time of the current series was
approximately 31 months. Although longer follow-up is
desired to document the long-term outcome, as majority
of local/regional recurrences occur in the first 24
months after the complication of radiation therapy
[18-20], a median follow-up of 31 months in our series
suggested that the true incidence of local and/or regio-
nal recurrence might approximate our findings.
Neoadjuvant chemotherapy was used in all patients
with locoregionally advanced NPC in our study. The
purpose of this strategy was to prevent disease progres-
sion during our long waiting period. While such a mea-
sure maybe necessary to prevent adverse outcome due
to limited resource, the addition of chemotherapy prior
to the start of IMRT may complicate interpretation of
local and regional control outcome. Neoadjuvant che-
motherapy is effective in reducing local recurrence with-
out affecting overall survival. However, as all patients
with stage III, stage IVA/B diseases, or with cervical
adenopathy of >4 cm in diameter received chemother-
apy prior to the start of IMRT, we consider neoadjuvant
chemotherapy not a confounder of this analysis for the
effect of concurrent chemotherapy. However, whether
neoadjuvant chemotherapy could be omitted in the
treatment of patients with locoregionally advanced NPC
using IMRT awaits further investigations.
The retrospective nature of the study certainly served
as an inherited and fundamental pitfall of the current
study. In addition, it is important to note the significant
imbalance between the patient groups treated with or
without concurrent chemotherapy: higher proportion of
female patients and higher proportion of patients with
stage III NPC received concurrent chemotherapy, as
compared to male and patients with stage IVA/B dis-
ease. Although such imbalances served a substantial
shortcoming for a retrospective study, it is equally
importantly to note that more patients with poorer
prognostic factors (male gender and higher stage) were
treated without concurrent chemotherapy, which is con-
sidered a less aggressive approach. Subgroup analysis
between patients treated with or without concurrent
chemotherapy resulted no significant differences in
treatment outcome. The imbalance in treatment modal-
ities but similar outcome suggested that concurrent che-
motherapy in the setting of conformal radiation therapy
using IMRT after neoadjuvant chemotherapy might not
provide further therapeutic value, even in patients with
more advanced disease and poor prognostic factor (i.e.,
male gender).
Clearly, further investigation, preferably in prospective
fashion, on the efficacy of chemotherapy delivered con-
currently with IMRT for locoregionally advanced NPC
is needed. A prospective randomized study is warranted
to confirm the additional therapeutic value of
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locoregionally advanced NPC. Such endeavor is not pos-
sible without multi-institutional efforts. Moreover, locor-
egionally advanced NPC include a heterogeneous group
of patients with T2b-T4N0M0 and anyTN1-3M0 dis-
eases. Differences in biological behavior between simi-
larly staged diseases, such as T4N0M0 (stage IVA)
versus T1N3M0 (stage IVB) are expected. In an insight-
ful editorial, Cooper generated three hypotheses on che-
moradiation therapy for NPC: 1. Concurrent
chemoradiation therapy might be an overtreatment for
stage II NPC; 2. Fine-tuning of the current treatment
strategy is needed for stage III NPC; And 3. More effec-
tive systemic therapy is needed for stage IV NPC [21].
The results of our series indicated that these hypotheses
needed to be addressed especially in the IMRT era. Our
sample size is too small to perform subgroup analyses
according to T- and N-classification as well as staging
groups of the disease. Therefore, whether concurrent
chemotherapy could be substituted with neoadjuvant
chemotherapy or omitted in certain subgroups or all
subgroups of advanced NPC is subject to further investi-
gation. Our results demonstrated that distant metastasis
was the major manifestation of treatment failure, and
lymph node status was the only significant prognostic
factor for metastatic-free survival and overall survival. In
addition, results from randomized trials and meta-ana-
lyses showed that no effect of adjuvant or neoadjuvant
chemotherapy on the long-term survival could be
demonstrated [5,17]. These findings emphasized that
more effective chemotherapy agents and regimens are
urgently needed for the treatment of subclinical meta-
static foci in locoregionally advanced NPC.
Conclusion
IMRT following neoadjuvant chemotherapy for locore-
gionally advanced NPC provided favorable outcome in
terms of 3-year local/regional control, MFS, DFS, and
OS. Our results further suggested that concurrent che-
motherapy offered no significant value for further
improvement of local and regional control to IMRT fol-
lowing neoadjuvant chemotherapy. In addition, the
extent of primary disease measured by T-classification
has no significant predictive value for prognoses, whereas
N-classification is the only significant prognosticator for
both MFS and OS. IMRT following neoadjuvant che-
motherapy is a strategy that deserves to be optimized and
then tested in a prospective randomized Phase III trial to
learn its efficacy in selected subgroups of patients with
locoregionally advanced nasopharyngeal carcinoma.
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